Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
03/2005
03/10/2005CA2536319A1 Amorphous, spray-dried powders having a reduced moisture content and a high-long term stability
03/10/2005CA2536246A1 Skeletally targeted nanoparticles
03/10/2005CA2536191A1 Nanoparticles for delivery of nucleic acids and stable double-stranded rna
03/10/2005CA2529027A1 D-amino acid peptides
03/10/2005CA2525374A1 Delivery of compounds with rehydrated blood cells
03/09/2005EP1512696A1 Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
03/09/2005EP1512429A1 Needles coated with vaccine
03/09/2005EP1512414A1 Hapten-carrier conjugates for treating and preventing nicotine addiction
03/09/2005EP1512410A1 Use of a composition for treating organ tissue injury caused by reperfusion of blood flow following a period of ischemia
03/09/2005EP1512405A1 Chloasma amelioration composition and dullness amelioration composition
03/09/2005EP1512404A1 External preparations for treating dermatitis
03/09/2005EP1512403A1 Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof
03/09/2005EP1512399A1 Porphyrin oxygen infusion preparation for increasing oxygen concentration in tumor tissue
03/09/2005EP1512398A1 Intravascular stent with cytoskeletal inhibitors for the prevention of restenosis
03/09/2005EP1512394A1 Universal controlled-release composition comprising chitosan
03/09/2005EP1511846A1 Self-coalescing or self-aggregating proteins derived from a membrane translocating sequence
03/09/2005EP1511811A2 Oil-soluble pigment compositions
03/09/2005EP1511790A1 Polyaminoacids functionalized by alpha tocopherol and uses thereof, particular for therapeutic applications
03/09/2005EP1511770A2 Immunoadhesin comprising a glycoprotein vi domain
03/09/2005EP1511763A2 Intracellular delivery of biological effectors
03/09/2005EP1511721A2 Guanidino phenylalanin compounds used as urokinase inhibitors
03/09/2005EP1511519A1 Modified byrodin 1 with reduced immunogenicity
03/09/2005EP1511518A2 Neutrophil imaging methods in cystic fibrosis
03/09/2005EP1511517A1 Formulation for parenteral administration of sodium channel blockers
03/09/2005EP1511516A1 Topically applicable pharmaceutical preparation
03/09/2005EP1511508A2 Method of treating dyslipidemic disorders
03/09/2005EP1511498A1 A method of treating human skin and a skin care composition for use in such a method
03/09/2005EP1511494A1 Androgen pharmaceutical composition and method for treating depression
03/09/2005EP1511490A2 Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods
03/09/2005EP1511489A1 New pharmaceutical compositions containing flibanserin polymorph a
03/09/2005EP1511487A1 Novel formulation for the parenteral application of crobenetine
03/09/2005EP1511486A1 Use of dopamine partial agonists for the treatment of the restless legs syndrome and corresponding pharmaceutical preparation
03/09/2005EP1511481A1 Ophthalmological use of roflumilast for the treatment of diseases of the eye
03/09/2005EP1511480A2 Inhibitors of glycoprotein vi
03/09/2005EP1511475A1 A herbal molecule as potential anti-leukemic drug
03/09/2005EP1511471A1 Colloidal suspension of submicronic particles for delivering active principles and method for preparing same
03/09/2005EP1511468A1 Nanoparticulate sterol formulations and sterol combinations
03/09/2005EP1511467A1 Nanoparticulate polycosanol formulations and novel polycosanol combinations
03/09/2005EP1511466A1 Use of glycosaminoglycans such as e.g. heparin for the treatment of respiratory disorders such as copd
03/09/2005EP1511378A2 Antifungal parenteral products
03/09/2005EP1448053A4 Proliferation and differentiation of stem cells using extracellular matrix and other molecules
03/09/2005EP1432407B1 Lisinopril compositions having large-particle dcpd
03/09/2005EP1401397B1 Pharmaceutical formulation having a masked taste and method for the production thereof
03/09/2005EP1303261B1 Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs
03/09/2005EP1255552B1 Prostaglandin compositions for the treatment for male erectile dysfunction
03/09/2005EP1231902B1 Film coating method for tablets
03/09/2005EP1194154B1 Use of propionic bacteria for producing propionic acid and/or propionates in the colon
03/09/2005EP1189971B1 Functional poly-alpha-aminoacid derivatives useful for the modification of biologically active materials and their application
03/09/2005EP1143950B1 Topical application products against onychomycoses
03/09/2005EP1124536B1 Propofol composition comprising pentetate
03/09/2005EP1054680B1 Treatment of bladder cancer by mycobacterium phlei cell wall
03/09/2005EP0991408B1 Novel process for manufacturing paroxetine solid dispersions
03/09/2005EP0935471B1 Mononuclear phagocytes in therapeutic drug delivery
03/09/2005EP0868438B1 Selective alkylations of cyclodextrins at the levels of minimal effective basicity
03/09/2005EP0784481B1 Wound healing formulations containing human plasma fibronectin
03/09/2005CN1592756A Chitosan preparation
03/09/2005CN1592755A Anti-angiogenic peptides
03/09/2005CN1592681A System, method and device for mfg. dosage forms
03/09/2005CN1592635A Autologous growth factor cocktail composition, method of production and use
03/09/2005CN1592633A T-cell epitodes in carboxypeptidase G2
03/09/2005CN1592630A Injection solution comprising an LHRH antagonist
03/09/2005CN1592629A L-methionine as a stabilizer for NESP/EPO in hsa-free formulations
03/09/2005CN1592622A Orodispersible tablets containing fexofenadine
03/09/2005CN1592618A Method of producing a processed kava product having an altered kavalactone distribution and processed kava products produced using the same
03/09/2005CN1592613A Drug form with different shapes of cores and shells
03/09/2005CN1592612A Drug form with core and shell
03/09/2005CN1592611A Modified release dosage forms
03/09/2005CN1592610A Modified release dosage forms
03/09/2005CN1592609A Abuse-resistant opioid dosage form
03/09/2005CN1592608A Micropherules containing a pleuromutilin derivative
03/09/2005CN1592607A Compositions and methods for delivery of poorly water soluble drugs and methods of treatment
03/09/2005CN1592600A Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections
03/09/2005CN1592585A Encapsulated materials
03/09/2005CN1592583A Capsule with fast content solubilization and release
03/09/2005CN1589908A Tenascin-C nucleic acid ligands
03/09/2005CN1589907A Controlled release medicine for ophthalmic disease
03/09/2005CN1589906A New oral formulation for 5-HT4 agonists or antagonists
03/09/2005CN1589775A New type floating retention slow release tablet not depending on acidity environment in stomach
03/09/2005CN1589774A Slow release medicine for treating alveolysis
03/09/2005CN1192102C Enzyme catalyzed therapeutic agents
03/09/2005CN1192057C Antibiotics-polymer composition
03/09/2005CN1191865C Stabilization of lipid DNA formulations during nebulization
03/09/2005CN1191864C Hemoglobin-polysaccharide conjugates
03/09/2005CN1191863C Formulations for protection of PEG-alpha interferon conjugates
03/09/2005CN1191857C potentiation of anti-CD38-immunotoxin cytotoxicity
03/09/2005CN1191854C Model membrane systems
03/09/2005CN1191834C Aciclovir compositions contg. dimethicone
03/09/2005CN1191829C Stable heptyl platinum solution preparation
03/09/2005CN1191826C Pharmaceutical formulation
03/09/2005CN1191823C Cell for producing alginate capsules
03/09/2005CN1191822C Prepn .of lipid blend and phospholipid suspension contg. the lipid blend
03/09/2005CN1191810C Hair treatment compositions comprising C20 or higher unsaturated fatty acid polyester of cyclic polyols
03/08/2005US6864383 Ophthalmic compositions for treating ocular hypertension
03/08/2005US6864373 Stable amorphous celecoxib composite and process therefor
03/08/2005US6864350 Soluble, degradable poly (ethylene glycol) derivatives for controllable release of bound molecules into solution
03/08/2005US6864274 Allantoin-containing skin cream
03/08/2005US6864258 PH sensitivity; controlling blood concentration; cardiovascular disorders
03/08/2005US6864246 Anticholesterol agents
03/08/2005US6864245 Polysaccharides; antidiabetic agents; Parkinson's disease
03/08/2005US6864227 Artery-and vein-specific proteins and uses therefor
1 ... 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 ... 1712